Gregor K J, Riley J A, Downing D K
PCS Health Systems, Inc., Scottsdale, Arizona.
Clin Ther. 1996 May-Jun;18(3):521-7; discussion 520. doi: 10.1016/s0149-2918(96)80034-8.
A retrospective drug utilization analysis was conducted to compare concomitant use of anxiolytics and hypnotics among patients who received selective serotonin reuptake inhibitors (SSRIs). Data were extracted from an administrative prescription claims database. Patients must have been 18 to 64 years of age, without antidepressant, anxiolytic, or hypnotic use before SSRI therapy initiation, and without the use of antidepressants, other than the original SSRI, after SSRI therapy initiation. The study sample included 117,319 patients. Concomitant anxiolytic use for the total sample was 9.8%. Concomitant anxiolytic use rates for the comparison groups were: fluoxetine, 9.5%; paroxetine, 11.4%; and sertraline, 9.5%. Concomitant hypnotic use for the total sample was 2.8%. Concomitant hypnotic use rates for the comparison groups were: fluoxetine, 2.5%; paroxetine, 3.5%; and sertraline, 2.8%. The majority of concomitant anxiolytic and hypnotic use was initiated on the same day as SSRI therapy initiation. The anxiolytic and hypnotic concomitant use rates for fluoxetine and sertraline patients were significantly lower than the concomitant use rates for paroxetine patients. An understanding of the clinical, quality-of-life, and economic implications of the concomitant use differences will require further study.
进行了一项回顾性药物利用分析，以比较接受选择性5-羟色胺再摄取抑制剂（SSRI）治疗的患者中抗焦虑药和催眠药的联合使用情况。数据从行政处方索赔数据库中提取。患者年龄必须在18至64岁之间，在开始SSRI治疗前未使用过抗抑郁药、抗焦虑药或催眠药，且在开始SSRI治疗后除最初的SSRI外未使用过其他抗抑郁药。研究样本包括117319名患者。整个样本中抗焦虑药的联合使用率为9.8%。各比较组的抗焦虑药联合使用率分别为：氟西汀9.5%；帕罗西汀11.4%；舍曲林9.5%。整个样本中催眠药的联合使用率为2.8%。各比较组的催眠药联合使用率分别为：氟西汀2.5%；帕罗西汀3.5%；舍曲林2.8%。大多数抗焦虑药和催眠药的联合使用是在开始SSRI治疗的同一天开始的。氟西汀和舍曲林患者的抗焦虑药和催眠药联合使用率显著低于帕罗西汀患者。对于联合使用差异的临床、生活质量和经济影响的理解还需要进一步研究。
